<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dexamethasone suppression tests
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dexamethasone suppression tests
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dexamethasone suppression tests
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hershel Raff, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         suppression tests (DSTs) are primarily used to screen for excess cortisol production (Cushing syndrome) and are useful in detecting dysregulated cortisol hypersecretion in adrenal incidentalomas. DSTs are less reliable for the evaluation of the differential diagnosis of corticotropin (ACTH)-dependent Cushing syndrome. Dexamethasone is approximately 30 to 40 times more potent than cortisol and has no appreciable mineralocorticoid activity. The DSTs assess the hypothalamic and pituitary corticotroph cell responses to glucocorticoid negative feedback inhibition of corticotropin-releasing hormone (CRH) and ACTH secretion.
        </p>
        <p>
         This topic will review the basic principles of the DSTs. Additional information on when to choose them to determine the diagnosis and the cause of Cushing syndrome is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/153.html" rel="external">
          "Evaluation and management of the adrenal incidentaloma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          LOW-DOSE DSTs
         </span>
        </p>
        <p class="headingAnchor" id="H265584205">
         <span class="h2">
          Indications and rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression tests (DSTs) are standard
         <strong>
          screening
         </strong>
         tests to differentiate patients with endogenous Cushing syndrome of any cause from patients who do not have Cushing syndrome. The 1 mg overnight DST is also used to identify modest excess cortisol secretion in patients with adrenal incidentalomas, primary aldosteronism (with cortisol co-secretion), or adrenocortical carcinoma without clinical signs of overt Cushing syndrome. The high-dose test described below should not be used for these purposes. (See
         <a class="local">
          'High-dose DSTs'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
         The binding of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         to glucocorticoid receptors in hypothalamic paraventricular nuclei and in pituitary corticotroph cells inhibits corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion. In humans, dexamethasone does not directly inhibit adrenal steroid production [
         <a href="#rid1">
          1
         </a>
         ]. If the hypothalamic-pituitary-adrenal (HPA) axis is functioning normally, any supraphysiologic dose of dexamethasone is sufficient to suppress pituitary ACTH secretion. This should reduce cortisol production, with concomitant decreases in serum, saliva, and urine concentrations.
        </p>
        <p>
         Two main protocols are used: the overnight 1 mg screening test and the two-day, low-dose test. Side effects are extremely rare, and either test can be conducted on an outpatient basis. The test should not be conducted if the patient is receiving exogenous ACTH, any type of glucocorticoid therapy, or is acutely ill or undergoing significant stress [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Overnight screening test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overnight 1 mg DST is a quick screening test [
         <a href="#rid3">
          3,4
         </a>
         ].
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         (1 mg) is taken orally between 11 PM and midnight, and a single blood sample is drawn at 8 AM the next morning for assay of serum cortisol and, if available, serum dexamethasone. A dose of 0.3 mg/m
         <sup>
          2
         </sup>
         surface area can be used in children [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H854152627">
         <span class="h3">
          Dose adjustments for adults with obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         We continue to suggest the standard 1 mg dose for the overnight screening DST, including for patients with obesity. While there have been concerns that individuals with obesity may require higher
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         doses, data are conflicting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 34 healthy weight (13 men and 21 women) and 87 adults with obesity (36 men and 51 women), pituitary sensitivity to feedback inhibition by
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in the group with obesity was preserved, even at doses lower than 1 mg [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, in a second series of 100 consecutive adults with obesity (body mass index [BMI] &gt;30 kg/m
         <sup>
          2
         </sup>
         ), a false-positive rate of morning plasma cortisol &gt;1.8 mcg/dL was found in 8 percent of individuals receiving 1 mg overnight
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , while it was only 2 percent in those receiving 2 mg overnight dexamethasone [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H991918276">
         <span class="h3">
          Normal results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Using current immunoassays (which are more specific for cortisol than older assays), most individuals suppress their 8 AM cortisol value to less than 2 mcg/dL (55 nmol/L) [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
         An occasional patient with Cushing disease will suppress to 1.8 mcg/dL (50 nmol/L), so this cutoff point is used to maximize sensitivity [
         <a href="#rid11">
          11-13
         </a>
         ]; it also appears to be valid when using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure serum cortisol [
         <a href="#rid14">
          14
         </a>
         ]. While structurally based assays such as LC-MS/MS fully discriminate between
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and cortisol, because serum dexamethasone levels are low and have limited cross-reactivity in immunoassays, structurally based assays are not required.
        </p>
        <p>
         A meta-analysis of 50 studies including 1531 patients with Cushing syndrome and 3267 control subjects reported that the 1 mg overnight DST using a cortisol cutoff of 1.8 mcg/dL (50 nmol/L) had the highest sensitivity (98.6 percent) and the lowest specificity (90.6 percent) compared with other initial tests for the diagnosis of Cushing syndrome [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2396080105">
         <span class="h3">
          Falsely normal results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite use of a diagnostic criterion chosen to improve sensitivity, some patients with Cushing disease suppress the 8 AM serum cortisol concentration to less than 1.8 mcg/dL (50 nmol/L) after the overnight DST [
         <a href="#rid9">
          9
         </a>
         ]. Because of this, it is important to obtain at least two screening tests. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review of a single practitioner's experience in 103 patients with Cushing syndrome showed that 6 of 80 (8 percent) suppressed to less than 2 mcg/dL (55 nmol/L) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 97 patients with Cushing syndrome using a slightly higher 1.5 mg
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         dose, four suppressed to between 1.2 and 2.8 mcg/dL (34 and 77 nmol/L) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H850448930">
         <span class="h3">
          Falsely abnormal results
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2008 Endocrine Society and 2021 Pituitary Society guideline update both suggest a diagnostic cortisol criterion of 1.8 mcg/dL (50 nmol/L), recognizing that this choice decreases specificity [
         <a href="#rid12">
          12,13
         </a>
         ]. The use of progressively higher cutoff points will reduce falsely abnormal results at the expense of failing to identify patients with Cushing syndrome.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This was illustrated by an Italian investigation of 137 individuals suspected of Cushing syndrome [
         <a href="#rid18">
          18
         </a>
         ]. The cutoff of 1.8 mcg/dL (50 nmol/L) identified 38 cases of Cushing syndrome with 100 percent sensitivity and a specificity of 91 percent. When using a cutoff of 5 mcg/dL (137 nmol/L), the sensitivity decreased to 87 percent, but the specificity increased to 97 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morning serum cortisol values between 1.8 and 7.2 mcg/dL could be false positive due to a variety of factors including failure to take or absorb the
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         properly [
         <a href="#rid19">
          19
         </a>
         ]. Simultaneous measurement of serum dexamethasone can identify such cases [
         <a href="#rid20">
          20-22
         </a>
         ]. Because of the possibility of a false result, the 1 mg low-dose dexamethasone test should not be used as the sole criterion for excluding or establishing the diagnosis of Cushing syndrome. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome", section on 'Initial testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1890461254">
         <span class="h3">
          Interpretation based upon assay used
         </span>
         <span class="headingEndMark">
          —
         </span>
         Modern immunoassays using monoclonal antibodies that have minimal cross-reactivity with endogenous steroids are likely to yield results similar to LC-MS/MS and have a cutoff of &lt;1.8 mcg/dL [
         <a href="#rid11">
          11,23,24
         </a>
         ]. Older studies that used higher cutoff points also used less specific assays. (See
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
         We do not recommend the routine use of salivary cortisol measurements for the overnight 1 mg DST, because results vary between assays [
         <a href="#rid25">
          25,26
         </a>
         ]. Although most salivary cortisol immunoassays are not affected by
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , a commonly used US Food and Drug Administration (FDA)-cleared salivary cortisol enzyme immunoassay has 19 percent cross-reactivity with dexamethasone so it cannot be used for the DST [
         <a href="#rid27">
          27
         </a>
         ]. If salivary cortisol is used, the assay should be validated for this purpose in patients with and without Cushing syndrome to provide an appropriate criterion for its interpretation [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Two-day, low-dose test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two-day test is used to assess suppressibility in patients with an equivocal overnight test or as an alternative to the overnight test.
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         0.5 mg is taken orally every six hours, usually at 8 AM, 2 PM, 8 PM, and 2 AM on each day, for a total of eight doses. This test is sometimes referred to as the two-day, 2 mg test, which refers to the number of days and the total daily dose (2 mg) (see
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         ). The dose can be modified in children who weigh less than approximately 45 kg [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Blood is drawn two or six hours after the last dose for measurement of cortisol and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (and ACTH, if desired).
        </p>
        <p>
         The normal response to the low-dose, two-day test consists of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no single established criterion for interpretation of the two-day test. When using current assays to measure serum cortisol, the same criterion for suppression is recommended for the 1 mg and 2 mg, two-day test: a serum cortisol &lt;1.8 mcg/dL (&lt;50 nmol/L). Using this criterion at 24 or 48 hours [
         <a href="#rid31">
          31
         </a>
         ], one retrospective study correctly identified 98 percent of 245 patients with Cushing syndrome [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smaller prospective studies using a serum cortisol concentration of 1.4 or 2.2 mcg/dL (38 or 60 nmol/L) at 48 hours as the exclusion criterion reported 90 to 100 percent sensitivity and 97 to 100 percent specificity in patients suspected of having Cushing syndrome [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therefore, the use of the two-day, low-dose test has greater specificity at high sensitivity than the 1 mg overnight test. As a result, this is the better screening test, with the caveat that it requires more patient effort than the 1 mg test to achieve excellent diagnostic results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because the overnight test is easier to administer, it is often the preferred test in the United States, but the two-day test often is used elsewhere because of its better performance. Although there are no formal studies validating this, the two-day, low-dose DST may be preferable to the overnight low-dose test when evaluating patients who are night-shift workers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary corticosteroid endpoints provide suboptimal sensitivity and specificity [
         <a href="#rid9">
          9,10,32
         </a>
         ]; serum cortisol endpoints should be used instead.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measuring plasma ACTH, if either of the tests is abnormal, gives an indication of the etiology of the hypercortisolism; it will usually be high normal or high in patients with the ectopic ACTH syndrome, within the normal range or elevated in those with Cushing disease, and low or undetectable in those with a primary adrenal source. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3297786140">
         <span class="h1">
          HIGH-DOSE DSTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         In theory, an 8 mg
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         dose (equivalent to more than 10 times the daily production of cortisol) should suppress ACTH secretion from corticotroph tumors, which generally retain some responsiveness to high-dose glucocorticoid negative feedback inhibition [
         <a href="#rid35">
          35
         </a>
         ]. In contrast, many nonpituitary tumors that produce ACTH ectopically (such as small cell lung carcinomas) do not contain active glucocorticoid receptors and are typically not responsive to glucocorticoid negative feedback.
        </p>
        <p>
         Unfortunately, there are pituitary corticotroph adenomas that do not suppress with the HDDST (particularly those with high ACTH production), and ectopic tumors that do [
         <a href="#rid36">
          36-38
         </a>
         ]. Therefore, the HDDST should not be used alone and should be interpreted in conjunction with a corticotropin-releasing hormone (CRH) stimulation test (where available) or
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         test and pituitary magnetic resonance imaging (MRI) if inferior petrosal sinus sampling is not available [
         <a href="#rid36">
          36,39-41
         </a>
         ].
        </p>
        <p>
         While some experts have abandoned the HDDST in favor of inferior petrosal sinus sampling alone, or the combined use of CRH and
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         stimulation tests [
         <a href="#rid13">
          13
         </a>
         ], the technical expertise and test agents for this approach are not universally available. In such situations, the HDDST should be interpreted in conjunction with the MRI and clinical features. For example, older age, male sex, rapid onset of symptoms, severe hypertension, hypokalemia, very high urine free cortisol and high plasma ACTH combined with a normal pituitary MRI and failure to suppress on the HDDST strongly suggests ectopic ACTH secretion. A more complete discussion of diagnostic strategies is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome", section on 'Petrosal venous sinus catheterization'
         </a>
         .)
        </p>
        <p>
         There are several HDDSTs that have been used:
        </p>
        <p class="headingAnchor" id="H3930058584">
         <span class="h2">
          Overnight 8 mg test
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         (8 mg) is taken orally between 11 PM and midnight. A single blood sample is drawn at 8:30 and 9 AM the day before and the next day for measurement of serum cortisol and, if one wishes, plasma ACTH and serum dexamethasone.
        </p>
        <p class="headingAnchor" id="H2974464054">
         <span class="h3">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The test is interpreted by calculating the suppression of morning serum cortisol concentration on the day before and after
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         administration, and considering a 50 to 80 percent or greater suppression to indicate Cushing disease [
         <a href="#rid42">
          42-45
         </a>
         ]. This approach yields 56 to 92 percent sensitivity and 57 to 100 percent specificity [
         <a href="#rid42">
          42,43,45-51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H417837337">
         <span class="h2">
          Other types of DSTs
         </span>
        </p>
        <p class="headingAnchor" id="H734136591">
         <span class="h3">
          Intravenous DSTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several versions of an intravenous
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression test (DST) have been proposed for initial confirmation and differential diagnosis of Cushing syndrome within one day, while avoiding the potential difficulties of drug compliance and absorption with oral dexamethasone. However, this approach has been evaluated in a limited number of patients, and we do
         <strong>
          not
         </strong>
         suggest its routine use.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         is infused at 1 mg/hour intravenously for four [
         <a href="#rid52">
          52,53
         </a>
         ], five [
         <a href="#rid54">
          54
         </a>
         ], or seven [
         <a href="#rid55">
          55
         </a>
         ] hours. Plasma cortisol is suppressed to levels &lt;1.4 to 3.0 mcg/dL (&lt;38 to 83 nmol/L) in the evening and the following morning in individuals with healthy weight and obesity, and it is above these levels at 9 AM in patients with Cushing syndrome (&gt;20 percent of baseline value or &gt;4.7 mcg/dL [130 nmol/L]), with a sensitivity and specificity of 100 and 90 percent, respectively [
         <a href="#rid53">
          53,55
         </a>
         ]. Using cortisol and ACTH values during the 4 mg intravenous DST, differentiation of Cushing disease (n = 32) from functional hypercortisolism (pseudo-Cushing n = 36) was achieved with a sensitivity of 100 percent and specificity of 83.3 percent [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3658012008">
         <span class="h1">
          SOURCES OF ERROR
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several common sources of error in
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression tests (DSTs):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute stress or illness
         </strong>
         –
         <strong>
         </strong>
         In general, DSTs should not be performed in patients who are critically ill and/or in the postoperative period. Acute stress, infection, and the immediate postoperative period activate the hypothalamic-pituitary-adrenal (HPA) axis so that suppression with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         may not be normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Elevated corticosteroid-binding globulin
         </strong>
         – Increased corticosteroid-binding globulin (CBG) levels may confound results in DSTs that use serum cortisol as an endpoint and result in an apparent lack of suppression to the low-dose DST [
         <a href="#rid57">
          57
         </a>
         ]. In this setting, salivary cortisol values, which reflect unbound cortisol, will show normal suppression [
         <a href="#rid58">
          58
         </a>
         ]. Thus, it may be more practical to evaluate individuals with elevated CBG levels using late-night salivary cortisol as a screening test [
         <a href="#rid59">
          59,60
         </a>
         ]. In 30 healthy women with elevated CBG levels, the two-day, low-dose DST yielded fewer false-positive results (27 percent) compared with the 1 mg DST (63 percent), whereas late-night salivary cortisol was normal in all [
         <a href="#rid61">
          61
         </a>
         ]. The diagnostic evaluation for Cushing syndrome in individuals with elevated CBG levels is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome", section on 'Available tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnancy leads to elevated CBG levels and HPA axis activity [
         <a href="#rid62">
          62-65
         </a>
         ]. In one study, CBG levels were still elevated in most women at two to three months postpartum [
         <a href="#rid66">
          66
         </a>
         ]. The diagnosis of Cushing syndrome in pregnancy is covered elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/139.html" rel="external">
          "Diagnosis and management of Cushing syndrome during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Variation in
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          intake or metabolism
         </strong>
         – Failure of the patient to take the
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         or abnormal metabolism of the dexamethasone can interfere with interpretation of the test. Drugs that induce hepatic CYP3A4 enzymes, such as barbiturates,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         increase the metabolism of dexamethasone and other steroids [
         <a href="#rid67">
          67,68
         </a>
         ]. Nearly one-half of the US Food and Drug Administration (FDA)-approved drugs in the United States interact with CYP3A4 and may confound the interpretation of any DST [
         <a href="#rid69">
          69
         </a>
         ]. These effects can be detected by measuring serum dexamethasone at the appropriate interval after the last dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid receptor polymorphisms
         </strong>
         – Several glucocorticoid receptor polymorphisms have been identified that confer increased glucocorticoid sensitivity. Individuals with N363S, GR9b, or BclI polymorphisms have greater serum cortisol reduction after
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         administration [
         <a href="#rid70">
          70
         </a>
         ]. In contrast, the ER22/23EK and A3669G polymorphisms are associated with decreased glucocorticoid sensitivity and relative glucocorticoid resistance [
         <a href="#rid71">
          71
         </a>
         ]. These glucocorticoid receptor polymorphisms are not determined on a clinical basis but may be implicated in some false-positive or negative response to dexamethasone tests [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         False-negative responses using the high-dose DST (HDDST) to identify patients with Cushing disease are more common with higher baseline corticotropin (ACTH) and cortisol secretion. In less than 5 percent of patients with Cushing disease, for example, higher doses of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (16 to 100 mg/day) were required to produce significant suppression. These patients tend to have large tumors and more severe hypercortisolism [
         <a href="#rid72">
          72-74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         False-positive responses to the 8 mg DST occur in some patients with ACTH-secreting neuroendocrine tumors (usually pulmonary, and mostly benign); occasionally other tumors respond to HDDST with decreased tumor secretion of ACTH and cortisol [
         <a href="#rid39">
          39,75,76
         </a>
         ]. Such tumors present a difficult diagnostic problem because they are often occult and may overlap with the clinical features of Cushing disease without the short course, severe hypercortisolism and hypokalemia considered more typical of ectopic ACTH secretion from malignant tumors such as small cell lung carcinomas. (See
         <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H976040411">
         <span class="h1">
          USE OF DEXAMETHASONE MEASUREMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measuring serum
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is suggested for all dexamethasone suppression tests (DSTs). It provides verification that the drug was taken and indicates whether the serum concentration is within the limits expected in an individual who metabolizes the drug normally. Laboratory nomograms and guidelines are available that relate serum dexamethasone concentrations to serum cortisol concentrations in normal subjects and in patients with Cushing disease [
         <a href="#rid19">
          19-22,77
         </a>
         ].
        </p>
        <p>
         Commercial laboratories often provide a range of expected values for a specific dose and interval until the blood draw. Finding an abnormally high or low serum
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         concentration allows one to interpret the cause of an unusual serum or urinary cortisol response and to repeat the test, if necessary, with the same or another dexamethasone dose.
        </p>
        <p>
         Using modern liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays, a serum
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         concentration of 3.3 to 3.6 nmol/L is sufficient to get appropriate suppression of morning serum cortisol [
         <a href="#rid14">
          14
         </a>
         ]. The reference range for serum dexamethasone measured at 8 AM following the 1 mg dose taken at 11 PM the night before is 140 to 295 ng/dL (3.6 to 7.5 nmol/L) [
         <a href="#rid20">
          20-22,78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2976626560">
         <span class="h1">
          USE OF DSTs IN SPECIAL POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression tests (DSTs) in each of these populations is discussed further in their specific topics.
        </p>
        <p class="headingAnchor" id="H3529735089">
         <span class="h2">
          Mild cortisol secretion in adrenal incidentalomas and other adrenal tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The low-dose DST is the preferred screening test used to identify mild autonomous cortisol secretion in patients with incidentally found adrenal masses. (See
         <a class="medical medical_review" href="/z/d/html/153.html" rel="external">
          "Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/138.html" rel="external">
          "Diagnosis of primary aldosteronism", section on 'Cortisol cosecretion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2189712009">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         The low-dose 1 mg overnight DST is not recommended to diagnose Cushing syndrome during pregnancy, because of the risk for false-positive results. Instead, the initial evaluation includes a late-night salivary cortisol and a 24-hour urinary cortisol. The 8 mg high-dose DST is sometimes performed to help determine etiology. The criteria for interpretation are different in these patients. (See
         <a class="medical medical_review" href="/z/d/html/139.html" rel="external">
          "Diagnosis and management of Cushing syndrome during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1958599886">
         <span class="h2">
          Primary pigmented nodular adrenocortical disease (PPNAD)
         </span>
         <span class="headingEndMark">
          —
         </span>
         A paradoxical increase in urinary free cortisol during the sequential low-dose (2 mg) and high-dose (8 mg) six-day
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression testing [
         <a href="#rid27">
          27
         </a>
         ] may be seen in patients with Cushing syndrome due to primary pigmented nodular adrenocortical disease (PPNAD) [
         <a href="#rid79">
          79
         </a>
         ]. This delayed "paradoxical" response can be useful to identify otherwise asymptomatic carriers in familial forms of PPNAD or to distinguish PPNAD from other adrenocortical tumors. (See
         <a class="medical medical_review" href="/z/d/html/152.html" rel="external">
          "Cushing syndrome due to primary pigmented nodular adrenocortical disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3579692411">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112709.html" rel="external">
          "Society guideline links: Diagnosis and treatment of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-dose
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          suppression test (DST)
         </strong>
         – The low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         suppression tests (DSTs; 1 mg overnight and two-day, low-dose) are used to differentiate patients with Cushing syndrome of any cause from patients who do not produce cortisol excess.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-dose DSTs (not for routine use)
         </strong>
         –
         <strong>
         </strong>
         The high-dose (8 mg) DSTs (HDDSTs) have been used for the differential diagnosis of corticotropin (ACTH)-dependent Cushing syndrome. The HDDST may be used with caution in conjunction with corticotropin-releasing hormone (CRH) test and/or
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         test, and pituitary magnetic resonance imaging (MRI) to assess the further requirement for inferior petrosal sinus sampling to confirm source of ACTH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          measurements
         </strong>
         –
         <strong>
         </strong>
         Simultaneous measurement of serum
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         concentration may be useful to confirm that the dexamethasone was taken, absorbed, and reached sufficient blood levels to exert glucocorticoid negative feedback.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sources of error
         </strong>
         – Increased corticosteroid-binding globulin (CBG) levels may result in an apparent lack of suppression to the low-dose DST. (See
         <a class="local">
          'Sources of error'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H99530126">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tuck ML, Sowers JR, Asp ND, et al. Mineralocorticoid response to low dose adrenocorticotropin infusion. J Clin Endocrinol Metab 1981; 52:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling JW, Raff H. DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome). Eur J Endocrinol 2017; 176:R205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin C, Igoe D, Duffy MJ, et al. The overnight dexamethasone test is a worthwhile screening procedure. Clin Endocrinol (Oxf) 1990; 33:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montwill J, Igoe D, McKenna TJ. The overnight dexamethasone test is the procedure of choice in screening for Cushing's syndrome. Steroids 1994; 59:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindmarsh PC, Brook CG. Single dose dexamethasone suppression test in children: dose relationship to body size. Clin Endocrinol (Oxf) 1985; 23:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquali R, Ambrosi B, Armanini D, et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab 2002; 87:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahin M, Kebapcilar L, Taslipinar A, et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med 2009; 48:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids 1989; 54:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood PJ, Barth JH, Freedman DB, et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997; 34 ( Pt 3):222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raverot V, Richet C, Morel Y, et al. Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys® Cortisol II assay. Ann Endocrinol (Paris) 2016; 77:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol 2021; 9:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueland GÅ, Methlie P, Kellmann R, et al. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol 2017; 176:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galm BP, Qiao N, Klibanski A, et al. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görges R, Knappe G, Gerl H, et al. Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999; 22:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceccato F, Barbot M, Zilio M, et al. Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. J Clin Endocrinol Metab 2015; 100:3856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meikle AW, Lagerquist LG, Tyler FH. Apparently normal pituitary-adrenal suppressibility in Cushing's syndrome: dexamethasone metabolism and plasma levels. J Lab Clin Med 1975; 86:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceccato F, Artusi C, Barbot M, et al. Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest 2020; 43:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roper SM. Yield of Serum Dexamethasone Measurement for Reducing False-Positive Results of Low-Dose Dexamethasone Suppression Testing. J Appl Lab Med 2021; 6:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogg N, Kurlbaum M, Deutschbein T, et al. Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clin Chem 2021; 67:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casals G, Hanzu FA. Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry? Ann Lab Med 2020; 40:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huayllas MKP, Netzel BC, Singh RJ, Kater CE. Serum Cortisol Levels via Radioimmunoassay vs Liquid Chromatography Mass Spectrophotometry in Healthy Control Subjects and Patients With Adrenal Incidentalomas. Lab Med 2018; 49:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrou Z, Guiban D, Maroufi A, et al. Overnight dexamethasone suppression test: comparison of plasma and salivary cortisol measurement for the screening of Cushing's syndrome. Eur J Endocrinol 1996; 134:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschbein T, Broecker-Preuss M, Flitsch J, et al. Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol 2012; 166:613.
          </a>
         </li>
         <li class="breakAll">
          https://salimetrics.com/assay-kit/salivary-cortisol-elisa-kit/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Homar PJ, Burns EA. Comparison of two methods for measuring salivary cortisol. Clin Chem 2002; 48:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersenn S. Biochemical diagnosis of Cushing's disease: Screening and confirmatory testing. Best Pract Res Clin Endocrinol Metab 2021; 35:101519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streeten DH, Stevenson CT, Dalakos TG, et al. The diagnosis of hypercortisolism. Biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives. J Clin Endocrinol Metab 1969; 29:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isidori AM, Kaltsas GA, Mohammed S, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:5299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy L, Atkinson AB, Johnston H, et al. Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed) 1984; 289:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishioka H, Yamada S. Cushing's Disease. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young J, Haissaguerre M, Viera-Pinto O, et al. MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 2020; 182:R29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Keyzer Y, Lenne F, Auzan C, et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996; 97:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Rodríguez E, Villar-Taibo R, Pinal-Osorio I, et al. Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome. Arq Bras Endocrinol Metabol 2008; 52:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi X, Du T, Zhu D, et al. High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing's syndrome. Endocrine 2022; 75:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruno OD, Rossi MA, Contreras LN, et al. Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 1985; 109:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aytug S, Laws ER Jr, Vance ML. Assessment of the utility of the high-dose dexamethasone suppression test in confirming the diagnosis of Cushing disease. Endocr Pract 2012; 18:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polat Korkmaz O, Karayel B, Korkmaz M, et al. RELIABILITY OF THE CORTICOTROPIN RELEASING HORMONE STIMULATION TEST FOR DIFFERENTIATING BETWEEN ACTH DEPENDENT AND INDEPENDENT CUSHING SYNDROME. Acta Endocrinol (Buchar) 2019; 15:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbot M, Trementino L, Zilio M, et al. Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. Pituitary 2016; 19:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dichek HL, Nieman LK, Oldfield EH, et al. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyrrell JB, Findling JW, Aron DC, et al. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 104:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Saadi N, Diederich S, Oelkers W. A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 48:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilar L, Freitas Mda C, Faria M, et al. Pitfalls in the diagnosis of Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belli S, Oneto A, Mendaro E. [Bilateral inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome]. Rev Med Chil 2007; 135:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousavi Z. Comparison of oral and intravenous high dose dexamethasone suppression test in the differential diagnosis of Cushing’s syndrome. Medical Journal of Mashhad University of Medical Sciences 2003; 46:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abou Samra AB, Dechaud H, Estour B, et al. Beta-lipotropin and cortisol responses to an intravenous infusion dexamethasone suppression test in Cushing's syndrome and obesity. J Clin Endocrinol Metab 1985; 61:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung C, Alford FP, Topliss DJ, et al. The 4-mg intravenous dexamethasone suppression test in the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 2010; 73:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croughs RJ, Docter R, de Jong FH. Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 1973; 72:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biemond P, de Jong FH, Lamberts SW. Continuous dexamethasone infusion for seven hours in patients with the Cushing syndrome. A superior differential diagnostic test. Ann Intern Med 1990; 112:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nouvel M, Rabilloud M, Raverot V, et al. Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome. Ann Endocrinol (Paris) 2016; 77:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic--pituitary--adrenal axis activity. Clin Endocrinol (Oxf) 2005; 63:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H. Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations. Endocrine 2013; 44:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambroziak U, Kondracka A, Bartoszewicz Z, et al. The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy. Clin Endocrinol (Oxf) 2015; 83:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carton T, Mathieu E, Wolff F, et al. Two-day low-dose dexamethasone suppression test more accurate than overnight 1-mg in women taking oral contraceptives. Endocrinol Diabetes Metab 2021; 4:e00255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott EM, McGarrigle HH, Lachelin GC. The increase in plasma and saliva cortisol levels in pregnancy is not due to the increase in corticosteroid-binding globulin levels. J Clin Endocrinol Metab 1990; 71:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr BR, Parker CR Jr, Madden JD, et al. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 1981; 139:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90:3077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005; 26:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab 2011; 96:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimaraki EV, Jaffe CA. Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab 2003; 88:3113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma RC, Chan WB, So WY, et al. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. BMJ 2005; 330:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J Clin Endocrinol Metab 2009; 94:4851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santen RJ, Jewell CM, Yue W, et al. Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids. J Clin Endocrinol Metab 2018; 103:3630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009; 1179:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur J Endocrinol 1998; 138:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katznelson L, Bogan JS, Trob JR, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998; 83:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flack MR, Oldfield EH, Cutler GB Jr, et al. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 1992; 116:211.
          </a>
         </li>
         <li class="breakAll">
          Orth DN. Ectopic hormone production. In: Endocrinology and Metabolism, Felig P, Baxter JD, Broadus AE, Frohman LA (Eds), McGraw-Hill, New York 1987. p.1692-1735.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 1982; 16:401.
          </a>
         </li>
         <li class="breakAll">
          https://www.esoterix.com/test-menu/44296/dexamethasone-mass-spectrometry.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratakis CA, Sarlis N, Kirschner LS, et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999; 131:585.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 160 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6257748" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mineralocorticoid response to low dose adrenocorticotropin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28179447" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2401096" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The overnight dexamethasone test is a worthwhile screening procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8073441" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The overnight dexamethasone test is the procedure of choice in screening for Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4028465" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Single dose dexamethasone suppression test in children: dose relationship to body size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11788642" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19122354" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2588297" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9158818" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022398" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27449530" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys®Cortisol II assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334580" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34687601" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Consensus on diagnosis and management of Cushing's disease: a guideline update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28298353" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32133504" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001614" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10342356" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26274344" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1151162" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Apparently normal pituitary-adrenal suppressibility in Cushing's syndrome: dexamethasone metabolism and plasma levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32060745" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33484119" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Yield of Serum Dexamethasone Measurement for Reducing False-Positive Results of Low-Dose Dexamethasone Suppression Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33997885" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32067427" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29608696" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Serum Cortisol Levels via Radioimmunoassay vs Liquid Chromatography Mass Spectrophotometry in Healthy Control Subjects and Patients With Adrenal Incidentalomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8590965" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Overnight dexamethasone suppression test: comparison of plasma and salivary cortisol measurement for the screening of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214924" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214924" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11751565" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Comparison of two methods for measuring salivary cortisol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33757676" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Biochemical diagnosis of Cushing's disease: Screening and confirmatory testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5808526" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The diagnosis of hypercortisolism. Biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602765" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8386285" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548938" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6437479" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13761950" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9177382" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31726770" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cushing's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31999619" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636444" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18820819" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34608552" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2990131" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21856594" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Assessment of the utility of the high-dose dexamethasone suppression test in confirming the diagnosis of Cushing disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31508176" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : RELIABILITY OF THE CORTICOTROPIN RELEASING HORMONE STIMULATION TEST FOR DIFFERENTIATING BETWEEN ACTH DEPENDENT AND INDEPENDENT CUSHING SYNDROME.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27236452" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8106630" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3004275" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9509067" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209858" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pitfalls in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18064362" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : [Bilateral inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of oral and intravenous high dose dexamethasone suppression test in the differential diagnosis of Cushing’s syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3998073" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Beta-lipotropin and cortisol responses to an intravenous infusion dexamethasone suppression test in Cushing's syndrome and obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20039897" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The 4-mg intravenous dexamethasone suppression test in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4739230" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158760" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Continuous dexamethasone infusion for seven hours in patients with the Cushing syndrome. A superior differential diagnostic test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26656734" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2139843" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16117823" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic--pituitary--adrenal axis activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23839587" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26173372" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34277979" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Two-day low-dose dexamethasone suppression test more accurate than overnight 1-mg in women taking oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2394772" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The increase in plasma and saliva cortisol levels in pregnancy is not due to the increase in corticosteroid-binding globulin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6258436" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705919" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cushing's syndrome during pregnancy: personal experience and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827110" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21367926" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843151" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695278" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850679" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30020469" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906240" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Clinical features associated with glucocorticoid receptor polymorphisms. An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506858" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886242" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9589666" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728204" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728204" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7094363" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7094363" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10523219" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
